This Cancer Drug War Is Just Getting Started
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 24, 11:41AM CST
The Food and Drug Administration approved Bristol-Myers Squibb 's Opdivo to treat melanoma on Monday. That's not very surprising given the strong clinical trial data the cancer drug has posted so far. In a trial of 120 patients without any other...
MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Merck Falls 2.97% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Dec 23, 3:47PM CST
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.03 to a high of $59.00. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $58.09 on volume of 14.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.46 (+0.25)
SmarTrend Watching for Potential Rebound in Shares of Merck After 2.97% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:46PM CST
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.03 to a high of $59.00. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $58.09 on volume of 14.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.46 (+0.25)
Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:30PM CST
Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014.
MDVN: 99.23 (+1.23), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01)
Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
Indexes Turn Mixed On Data; Celgene Dives
at Investor's Business Daily - Tue Dec 23, 9:43AM CST
Stocks backed off early gains and were mixed early Tuesday as investors wrestled through a jumble of economic news. The Dow Jones industrial average rose 0.4% and the S&P 500 added 0.2% as both indexes reached new highs. The Nasdaq shed its early...
DDS: 122.53 (+0.53), BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), ABG: 77.12 (+0.43), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)
Jim Cramer on the Markets: Some Stocks You Just Can't Ignore
at The Street - Tue Dec 23, 9:03AM CST
And stop chasing stocks that won't let you in.
FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), SWKS: 74.32 (+0.92), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), DIS: 94.42 (-0.27), BA: 131.24 (+1.21), MS: 38.81 (-0.14), AA: 15.77 (+0.04), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), COST: 143.65 (-0.50), CVS: 97.89 (+0.02), MCD: 93.83 (-0.39), GOOGL: 536.93 (-1.84), ROST: 92.72 (-0.60)
Who Is The Devil? Will Gilead Fall Or Soar In 2015?
Pharma Doc - Seeking Alpha - Tue Dec 23, 6:27AM CST
On December 19, 2014, Abbvie's (NYSE: ABBV ) Viekira Pak received US approval for HCV GT1 patients with or without ribavirin with a minimum of 12 weeks of treatment for a cost of $83.3k. As an avid contributor in this area, I wrote a comprehensive...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 2.95 (-0.01), MRK: 57.46 (+0.25)
Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results
at The Street - Mon Dec 22, 10:36AM CST
These Achillion results aren't great because the speed at which drugs kill the hepatitis C virus matters. Slower-acting drugs leave patients vulnerable to viral rebound or relapse.
GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25)
Next Support Level for Merck (MRK) is $58.61
Comtex SmarTrend(R) - Mon Dec 22, 10:12AM CST
Shares of Merck (NYSE:MRK) have bearishly opened below the pivot of $59.50 today and have reached the first support level of $59.09. Investors may be interested in a cross of the next downside pivot targets of $58.61 and $57.72.
MRK: 57.46 (+0.25)
Stocks Struggle To Hold Gains; Alaska Air, Spirit Up
at Investor's Business Daily - Mon Dec 22, 9:34AM CST
Stocks got off to a mixed start, but quickly turned positive in the shortened holiday week, with drugmakers showing particular weakness at Monday's open. The Dow Jones industrial average led, up 0.4%. The Nasdaq backed out of early losses to a 0.2%...
BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), SAVE: 75.68 (+1.52), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), ALK: 58.72 (+1.97), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Could Gilead Sciences, Inc. Be a Top Stock in 2015?
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 22, 8:46AM CST
GILD data by YCharts Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences shareholders -- through the weekend, Gilead shares had nearly quintupled the...
GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86)
BARDA awards Ebola vaccine contract to NewLink Genetics
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:44AM CST
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
GlobeNewswire - Mon Dec 22, 7:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)
Merck begins tender offer to acquire Cubist
M2 - Mon Dec 22, 6:43AM CST
Healthcare company Merck (NYSE:MRK) said on Friday that its subsidiary has started a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST).
CBSTZ: 0.06 (+0.01), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Could the Next Generation of Diabetes Treatments Be Found in This Illegal Drug?
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 21, 10:41AM CST
Heart disease and cancer may be the two most common direct causes of death in the United States, but a chronic disease that now affects 29.1 million people in this country and is a prime risk factor for heart disease, cancer, and...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)
Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 6:14AM CST
Source: GlaxoSmithKline plc GlaxoSmithKline reported late stage trial results for a promising new vaccine for the prevention of shingles that could help millions of people, and in the process win away sales from Merck & Co .'s shingles...
PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), GSK: 42.85 (+0.11)